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Abstract
E3 ubiquitin ligases are a large family of proteins that
are engaged in the regulation of the turnover and ac-
tivity of many target proteins. Together with ubiquitin-
activating enzyme E1 and ubiquitin-conjugating
enzyme E2, E3 ubiquitin ligases catalyze the ubiquiti-
nation of a variety of biologically significant protein
substrates for targeted degradation through the 26S
proteasome, as well as for nonproteolytic regulation
of their functions or subcellular localizations. E3
ubiquitin ligases, therefore, play an essential role in
the regulation of many biologic processes. Increasing
amounts of evidence strongly suggest that the ab-
normal regulation of some E3 ligases is involved in
cancer development. Furthermore, some E3 ubiquitin
ligases are frequently overexpressed in human can-
cers, which correlates well with increased chemo-
resistance and poor clinic prognosis. In this review,
E3 ubiquitin ligases (such as murine double minute 2,
inhibitor of apoptosis protein, and Skp1–Cullin–F-box
protein) will be evaluated as potential cancer drug
targets and prognostic biomarkers. Extensive study in
this field would lead to a better understanding of the
molecular mechanism by which E3 ligases regulate
cellular processes and of how their deregulations con-
tribute to carcinogenesis. This would eventually lead
to the development of a novel class of anticancer drugs
targeting specific E3 ubiquitin ligases, as well as the
development of sensitive biomarkers for cancer treat-
ment, diagnosis, and prognosis.
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Introduction
The ubiquitin–proteasome pathway is a major pathway
for the targeted degradation of proteins and involves
multistep enzymatic reactions catalyzed by a cascade of
enzymes, including ubiquitin-activating enzymeE1, ubiquitin-
conjugating enzyme E2, and ubiquitin ligase E3. Ubiquitin
is first activated by binding to E1 through a thioester bond
between a cysteine residue at the active site of E1 and the
C-terminus glycine (G76) of ubiquitin. Activated ubiquitin
in an E1–ubiquitin complex is then transferred to E2, which
also forms a thioester bond between its active-site cysteine
residue and the G76 of ubiquitin. Finally, ubiquitin is covalently
attached to the target protein through an isopeptide bond
between the G76 of ubiquitin and the q amino group of an
internal lysine residue of the target protein, catalyzed by E3
ubiquitin ligase. Through multiple runs of reactions, ubiquitin is
covalently attached to substrates to form K48-linked poly-
ubiquitinated conjugates that are rapidly recognized and de-
graded by the 26S proteasome [1]. Recent data have shown
that proteins can also be monoubiquitinated or polyubiquiti-
nated through K63 linkage, leading to altered protein activity
and subcellular localization, rather than degradation [2,3]. A
diagram of ubiquitination reaction and the three potential fates
of proteins after ubiquitination are illustrated in Figure 1.
E3 ubiquitin ligase is an enzyme that binds to specific protein
substrates and promotes the transfer of ubiquitin from a thio-
lester intermediate to amide linkages with proteins or poly-
ubiquitin chains [4]. Because they serve as the specific
substrate-recognition element of the system, E3 ligases play
an important role in ubiquitin-mediated proteolytic cascade.
There are approximately 1000 E3 ligases in the human genome
that can be classified into three major types, based on their
domain structure and substrate recognition. The first class
comprises N-end rule ubiquitin ligases that target protein sub-
strates bearing specific destabilizing N-terminal residues, in-
cluding Arg, Lys, His (type I), and Phe, Trp, Leu, Tyr, and Ile
(type II) [5]. One recent example of protein degradation by the
Ub-dependent N-end rule pathway is Drosophila inhibitor of
apoptosis protein (IAP) [6]. The second type of E3 is HECT, with
the first family member being E6-associated protein (E6-AP),
which, together with oncoprotein E6, promotes p53 ubiqui-
tination and degradation [7]. HECT E3 ligases contain an
approximately 350–amino acid C-terminal region homologous
to that of E6-AP, with a conserved active-site cysteine residue
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near the C-terminus, through which HECT domain E3 ligases
form thioester intermediates with Ub [8,9]. N-terminal regions
are highly variable and may be involved in substrate recog-
nition [4]. The third and largest type of E3 ligase is the Really
Interesting NewGene (RING) family, which contains a classic
C3H2C3 or C3HC4 RING finger domain [10] with a charac-
teristic linear sequence of Cys-X2-Cys-X9–39-Cys-X1–3-His-
X2–3-Cys/His-X2-Cys-X4–48-Cys-X2-Cys, where X can be
any amino acid. A RING finger domain binds to two zinc
atoms per molecule in a cross-braced system, where the
first and third pairs of cysteine/histidine form the first binding
site and where the second and fourth pairs of cysteine/
histidine form the other [11].
E3 ubiquitin ligases exist and act as a single peptide [such
as murine double minute 2 (Mdm2) and X-linked IAP (XIAP)]
or as multiple component complexes [such as Skp1–Cullin–
F-box protein (SCF)]. Through the covalent modification of a
vast repertoire of cellular proteins with ubiquitin, E3 ubiquitin
ligases regulate almost all aspects of eukaryotic cellular
functions and biologic processes. Accumulating data have
strongly suggested that deregulation of E3 ligases contrib-
utes to cancer development and that overexpression of E3
ligases is often associated with poor prognosis [12,13]. Thus,
E3 ligases, which determine the specificity of protein sub-
strates and are themselves ‘‘drugable’’ enzymes, can serve
as potential cancer targets as well as cancer biomarkers.
E3 Ubiquitin Ligases as Potential Cancer Targets
An ideal cancer target meets the following criteria: 1) it plays
an essential role in cancer genesis, and/or is required for the
maintenance of cancer cell phenotype, and/or is apoptosis-
protective and confers cancer cells resistance to apoptosis;
2) it is overexpressed in cancer cells, and its overexpression
is associated with a poor prognosis of patient survival; 3)
inhibition of its expression or activity induces growth suppres-
sion and/or apoptosis in cancer cells; 4) it is ‘‘drugable,’’
meaning that it is an enzyme (e.g., kinase) or a cell surface
molecule (e.g., membrane-bound receptor) that can be
easily screened for small-molecule inhibitors or that can be
targeted by a specific antibody; and 5) most importantly, it is
not expressed or is expressed at a very low level in normal
cells, and its inhibition has a minimal effect on normal cell
growth and function. Thus, inhibition of such a target would
achieve a maximal therapeutic index with minimal toxicity.
The E3 ubiquitin ligases discussed below would meet some
of these criteria.
Mdm2 E3 Ubiquitin Ligase and p53
Mdm2encodes a 90-kDa protein that was first identified as
the gene responsible for the spontaneous transformation of
an immortalized murine cell line BALB/c 3T3 [14]. It contains
a p53-binding domain at the N-terminus and a RING do-
main at the C-terminus. The p53-binding domain of Mdm2
or Hdm2 (human counterpart of Mdm2) binds to the tumor
suppressor p53, whereas the RING domain acts as an E3
ubiquitin ligase to promote rapid degradation of p53 [15–19].
Both in vitro and in vivo studies indicated that oncogenic
activity of Mdm2 is mainly attributable to its binding and
degradation of p53 [20,21]. p53 is a classic tumor sup-
pressor that is inactivated in more than 50% of human
cancers. Under unstressed conditions, the p53 level is very
low in cells due to Mdm2 binding and degradation. On DNA
damage by ionizing radiation or anticancer drugs, p53–
Mdm2 binding is dissociated as a result of p53 phosphoryla-
Figure 1. Ubiquitin pathways in the regulation of protein degradation and function. Ubiquitin is first attached to E1 ubiquitin-activating enzyme in the presence of
ATP. The activated ubiquitin is then transferred to E2 ubiquitin-conjugating enzyme. E3 ubiquitin ligase recognizes a protein substrate, recruits a E2–ubiquitin
complex, and catalyzes ubiquitin transfer from E2 to substrate. A single run of the reaction causes monoubiquitination of a target protein that could change its
function, whereas multiple runs of the reaction lead to polyubiquitination of the substrate. Depending on ubiquitin–ubiquitin linkage, polyubiquitinated proteins can
either be activated (through K63 linkage), or recognized and degraded by the 26S proteasome (through K48 linkage).
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tion and acetylation, leading to p53 activation. Activated p53
acts as a transcription factor that transactivates a number
of genes, leading to growth arrest (to repair damaged DNA)
or apoptosis (if damage is too severe to repair) [22].
Because Hdm2 plays a critical role in the regulation of p53
level, Hdm2 appears to be a promising cancer target whose
inhibition should lead to p53 reactivation and apoptosis
induction in human cancer cells harboring wild-type p53.
Indeed, Hdm2 as a cancer drug target has been extensively
validated. The approaches used include: 1) the blockage of
Hdm2–p53 interaction with synthetic peptides or monoclonal
antibodies [23,24]; and 2) the reduction of Hdm2 levels with
antisense oligonucleotides or siRNA [25–27]. As conse-
quence of Hdm2 targeting, the levels of p53 increased,
followed by transactivation of p53 downstream target genes
and induction of growth arrest and apoptosis [23–27]. All
these proof-of-concept studies support the notion that Hdm2
appears as a cancer target for the discovery and develop-
ment of a new class of small molecular antagonists. Indeed,
two classes of small molecules that target Mdm2 to reactivate
p53 and to induce apoptosis have been discovered so far:
the first class comprises inhibitors of Mdm2 E3 ubiquitin
ligase and the second class comprises compounds that
disrupt Mdm2–p53 binding, as illustrated in Figure 2.
Hdm2 E3 ligase inhibitor
A family of small molecules—HLI98 series—was identi-
fied through an HTS of a chemical library of 10,000 com-
pounds using an in vitro Hdm2 autoubiquitination assay [28].
Follow-up experiment showed that the compound indeed
inhibited Hdm2 activity, as well as other E3 ligases and even
E2 ligases at higher concentrations. In cell-based assays, the
compound stabilized p53 and Mdm2, and activated p53-
dependent transcription and apoptosis, but also had p53-
independent cytotoxicity. Furthermore, as expected, the com-
pound worked much better in cancer cells containing wild-
type p53 than in those containing mutant p53 because
targeting Hdm2 should, in theory, have little or no effect on
human cancers with mutant p53. However, in vivo antitumor
activity of HLI98, using human xenograft models, has not
been reported [28]. Nevertheless, this proof-of-concept study
indicated that Hdm2 E3 is a valid cancer target and that it is
possible to identify more potent inhibitors of Hdm2 E3 ligase
as a novel class of anticancer drugs for future discovery
and development.
Compounds disrupting Hdm2–p53 binding
Three classes of structurally distinctive compounds,
namely, Nutlin, RITA (Reactivation of p53 and Induction of
Tumor cell Apoptosis), and a nonpeptide Mdm2 inhibitor (MI-
17), were reported to disrupt Hdm2–p53 binding [29–31].
Historically, it has been difficult to develop small-molecule
inhibitors to disrupt large protein–protein interactions. How-
ever, the crystal structure of Mdm2–p53 peptide binding
revealed that binding relies on the contact of the p53 peptide
side chains of Phe19, Trp23, and Leu26 with the N-terminus
ofMdm2 (amino acids 17–125) in a deep hydrophonic pocket
[32], which made it possible for small molecules to disrupt
binding. Indeed, the Nutlin series was identified through a
screening of a diverse library that disrupted Mdm2–p53
peptide binding [31], whereas structure-based design on
Mdm2–p53 binding pocket led to identification of a potent
nonpeptide Mdm2 inhibitor MI-17 with a chemical structure
different from that of Nutlin [29]. Conversely, RITA was
Figure 2. Targeting Mdm2 E3 for p53 accumulation and apoptosis induction. Mdm2 binds to p53 through its N-terminal p53-binding domain and promotes p53
ubiquitination and degradation through its C-terminal RING domain. Two classes of small-molecule compounds were discovered. The first class comprises the
inhibitor Mdm2 E3 ligase HLI98C, and the second class comprises inhibitors that either disrupt Mdm2–p53 binding (Nutlin-1 or MI-17) or bind to p53 to inhibit its
binding to Mdm2 (RITA). The net effects of these small molecules are p53 accumulation and apoptosis induction.
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identified through a cell proliferation assay using a pair of
isogenic cancer cell lines differing in p53 status. RITA bound
to p53 and prevented p53–Hdm2 interaction [30]. Compared
to Hdm2 E3 ligase inhibitors, Mdm2–p53 binding inhibitors
appeared to be much more potent and specific in activating
the p53 pathway, leading to growth arrest, apoptosis, and in
vivo tumor growth inhibition. Again, mechanistically, these
compounds will only work in human cancers harboring wild-
type p53 and, preferentially, with Mdm2 overexpression. This
certainly turned out to be the case [29–31].
Two major concerns are associated with these com-
pounds, which induce p53 accumulation through Mdm2
manipulation. The first concern is the therapeutic window
or the selectivity between normal and cancer cells. Although
it is still unclear mechanistically, the activation of p53 in
normal cells by these compounds mainly caused growth
arrest, rather than apoptosis, making it possible to achieve
a therapeutic window by adjusting the dose regime and the
duration of the treatment [29] (S. Wang, personal communi-
cation). The second concern is the oncogenic activity of
Mdm2 independent of p53. Because Mdm2 itself is a p53
target, p53 activation, as a result of either approach, would
cause significant accumulation of Mdm2. An increased
amount of even ligase-deficient Hdm2might actually promote
tumor growth [33]. This potential side effect needs to be
further addressed. Finally, in addition toMdm2, two additional
RING proteins, COP1 [34] and PIRH2 [35], were determined
to be p53 targets and to promote p53 ubiquitination and
degradation. Indeed, COP1 and PIRH2 were overexpressed
in a subset of human cancers with increased p53 ubiquitina-
tion [36,37]. Further validation of COP1 and PIRH2 as
promising cancer targets is a prerequisite to initiating a library
screen for their specific inhibitors.
IAP and Caspases
The IAP family has at least eightmembers, including XIAP,
cIAP-1, cIAP-2, Ts-IAP, NAIP, survivin, Livin/ML-IAP, and
Apollon/Bruce [38–41]. They all contain one or several
baculovirual IAP repeat (BIR) domains that are required for
the suppression of apoptosis. Some family members also
have a RING finger domain at the C-terminus for the ubiq-
uitination and degradation of caspases [39,42,43]. In XIAP,
BIR3 (the third BIR domain) potently inhibits the activity of
the active caspase-9, whereas the linker region between
BIR1 and BIR2, as well as the BIR2 domain itself, selectively
targets active caspase-3 or caspase-7 [44,45]. Thus, IAP
suppresses apoptosis by binding to and by inhibiting active
caspase-3, caspase-7, and caspase-9 through BIR domains
[38,39,46]. In apoptotic cells, caspase inhibition by IAP is
negatively regulated by a mitochondrial protein, second
mitochondria-derived activator of caspase (Smac). Smac
physically interacts with multiple IAPs and relieves their
inhibitory effect on caspase-3, caspase-7, and caspase-9.
Smac binds to the BIR3 domain of XIAP through four
N-terminal residues (AVPI) that recognize a surface groove
on BIR3. These four amino acids are conserved in three
Drosophila proteins (Reaper, Grim, and Hid) that induce
apoptosis by eliminating the binding of Drosophila IAP
to caspases [47,48].
IAP as a promising cancer target has been extensively
validated by overexpression, silencing, or the use of a Smac-
derived AVPI peptide that binds to IAPs to free up caspases.
Indeed, overexpression of IAP suppressed apoptosis in-
duced by a variety of stimuli [39,49], whereas downregulation
of XIAP or survivin through antisense RNA or siRNA has
been shown to induce apoptosis in many human cancer cell
lines [50–57]. Furthermore, Smac peptide consisting of AVPI
sequence sensitized many human cancer cells to apoptosis
induced by conventional cancer therapies both in vitro and
in vivo [58–61], indicating that it is feasible to identify AVPI-
like small molecules to disrupt IAP–caspase binding. The
current effort, therefore, was focused on IAP–caspase bind-
ing inhibitors. Analogous to the Mdm2–p53 case, the use
of small molecules to disrupt protein–protein binding was
made possible by a well-defined small binding packet be-
tween the IAP BIR3 domain and the AVPI peptide of Smac
[47,48]. At least five classes of such compounds have been
discovered so far, and their structures have been summa-
rized in a recent review article [62].
The first class comprises tripeptides of unnatural amino
acids that were developed through a structure-based design
targeting the BIR3 domain of XIAP. The compounds induced
apoptosis in a number of human cancer cell lines by releasing
active caspase-9 from XIAP binding [63,64]. The structure-
based computational screening of a three-dimensional
structure database of traditional herbal medicines led to the
discovery of embelin as a potent inhibitor of XIAP–caspase-9
binding [65]. Embelin activated caspase-9, inhibited cell
growth, and induced apoptosis in prostate cancer cells
with high levels of XIAP, with minimal effect on normal pros-
tate epithelial and fibroblast cells, containing low levels of
XIAP expression [65].
The next two classes comprise compounds targeting
BIR2 or BIR2 link regions to disrupt binding to caspase-3.
Aryl sulfonamide, identified through the biochemical screen-
ing of a combinatorial chemical library, disrupted XIAP–
caspase-3 interaction and sensitized cancer cells to the
activator of the death receptor pathway [66]. A polyphenyl-
ureas series was identified with chemical library screening
using an enzyme derepression assay by overcoming XIAP-
mediated suppression of caspase-3 [67]. These series of
compounds indeed increased caspase activity, had broad
activity against cancer cell growth as tested in 60 NCI cancer
cell lines, sensitized cancer cells to chemotherapeutic
drugs, and inhibited tumor cell growth in xenograft models
in mice with limited toxicity to normal tissues [67]. This class
of compounds has been shown recently to activate caspase-
3 and caspase-7 and to directly induce the apoptosis of
leukemia cell lines and primary samples from acute mye-
logenous leukemia patients without much lethal effect on
normal hematopoietic cells [68].
Finally, a Smac mimic small-molecule compound was
identified through structure-based design using computer-
simulated conformations of AVPF as a guide. The compound
bound to XIAP, c-IAP1, and c-IAP2 to activate caspase-3
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and sensitized cancer cells to apoptosis induced by
TNF[tumor necrosis factor]-related apoptosis-inducing ligand
(TRAIL) and tumor necrosis factor a [69]. We further eval-
uate the compound in three breast cell lines with various
levels of IAP. Acting alone, Smac mimic compound was quite
potent with a cytotoxic IC50 of 3.8 nM in high IAPs expressing
MDA-MB-231 cells, but was inactive at a much higher con-
centration in low IAPs expressing T47D and MDA-MB-453
cells. In fact, as low as 2.5 nM Smac mimic alone was
sufficient to activate caspase-3 and to induce apoptosis in
MDA-MB-231 cells. In combination treatments with TRAIL or
etoposide, Smacmimic significantly sensitized cells to growth
suppression and apoptosis in MDA-MB-231 cells, but to
much lesser extent in T47D and MDA-MB-453 cells. Thus,
in these cell lines, Smacmimic compound acts in an apparent
IAP-dependent manner to induce apoptosis alone, as well as
to sensitize breast cancer cells to TRAIL- or etoposide-
induced apoptosis through caspase-3 activation [70].
All these studies showed convincingly that IAPs are valid
cancer targets and that disrupting their binding to caspases
would release active caspases to induce apoptosis prefer-
entially in IAPs overexpressing human cancer cells, with
less toxicity on normal cells having low IAP expression. Con-
versely, IAPs have been shown to act as ubiquitin ligases to
promote the ubiquitination and degradation of caspase-3,
caspase-9, and Smac [71–74]; mutations of the RING do-
main, which are required for E3 ligase activity, reduced the
apoptotic activity of XIAP [46]. Thus, targeting their ubiquitin
ligases appears to be a feasible approach to increasing the
levels of caspases and Smac, thus inducing apoptosis in
cancer cells or sensitizing cancer cells to conventional
cancer therapies. It is of concern that even ligase activity is
inhibited, however, IAPs may still bind to caspases and
prevent caspase activation and apoptosis induction. Thus,
specific inhibitors of IAP E3 ligase, which are yet to be
discovered, would be more effective in combination therapy
with chemotherapeutic drugs or IAP–caspase binding inhib-
itors. Figure 3 illustrates IAP targeting to activate caspases
and to induce apoptosis.
SCF E3 Ubiquitin Ligases and Their Substrates
SCF and SCF-like complexes comprise the largest family of
E3 ubiquitin ligases that consist of Skp1, Cullins, F-box
protein, and ROC/Rbx/SAG (Sensitive to Apoptosis Gene)
RING finger protein [75,76]. The crystal structure of the
SCF–Rbx complex revealed that Cul-1 acts as a scaffold
that binds Skp1–F-boxSkp2 (the protein substrate-recognition
complex; at its N-terminus) andRbx1 (which recruits E2; at its
C-terminus) [77]. Thus, SCF E3 ubiquitin ligases may serve
as scaffolds that position substrates andE2 enzymeoptimally
for ubiquitin transfer. Through various F-box proteins acting
as substrate receptors [78], SCF ligases recognize many
protein substrates and promote their ubiquitination and deg-
radation, thus regulating a variety of biologic processes
[75,76]. For example, through Skp2, which binds to cyclin-
dependent kinase inhibitors p27, p21, and p57, SCF E3
promotes their ubiquitination and degradation, thus promot-
ing G1!S progression [79–81]. Skp2 also binds to c-Myc
to promote its ubiquitination and degradation and, at the
same time, acts as a coactivator to enhance c-Myc–induced
S-phase transition and to activate c-Myc target genes [82,83].
Through the F-box protein b-TrCP, SCF E3 ligase promotes
the ubiquitination and degradation of Emi-1 (early mitotic
inhibitor), an inhibitor of the anaphase-promoting complex,
to control meiotic and mitotic progression [84,85]. b-TrCP
also binds to InB and b-catenin and, together with other
components of SCF ligase, promotes their ubiquitination
and degradation [86–94], thus regulating NFnB and Wnt
signaling pathways. Accumulated evidence strongly sug-
gested that abnormal regulations of SCF E3 ubiquitin ligase
contribute to uncontrolled proliferation, genomic instability,
and cancer [13].
The validation of whether SCF E3 ubiquitin ligase is an
appealing cancer target has been mainly focused on its
components, particularly Skp2, b-TrCP, and SAG, using
either overexpression or silencing (through antisense or
siRNA) approaches. Skp2 overexpression in gastric carcino-
ma cells decreased the level of p27, increased cell growth
rate, rendered cancer cells more resistant to actinomycin
D–induced apoptosis, and increased their invasion potential
[95]. Tissue-specific expression of Skp2 in the prostate gland
of a mouse transgenic model caused significant downregu-
lation of p27 level and marked tissue overproliferation, lead-
ing to hyperplasia, dysplasia, and low-grade carcinoma [96].
Skp2, when targeted for expression in T-lymphoid lineage,
cooperated with activated N-Ras to induce T-cell lymphomas
with a short latent period and high penetrance, indicating
that Skp2, as a protooncogene, is involved in the pathogen-
esis of lymphomas [97]. Conversely, downregulation of Skp2
using an antisense oligonucleotide remarkably suppresses
Figure 3. Targeting IAPs for caspase activation and apoptosis induction. IAP
binds to caspases through its BIR2 or BIR3 domain and promotes the
ubiquitination and degradation of caspases (Casps) through its C-terminal
RING domain. Small-molecule inhibitors that disrupt IAP–caspase binding
(AVPI-like) or yet-to-be discovered IAP E3 ligase inhibitor (E3I) would either
release caspases or induce accumulation of caspases, leading to apop-
tosis induction.
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the growth of small cell lung cancer cells [98]. siRNA silencing
of Skp2 has been shown to inhibit the growth of melanoma
cells [99], oral cancer cells [100], glioblastoma cells [101],
and lung cancer cells [102,103]. Similarly, overexpression
of b-TrCP increased NFnB activity and chemoresistance,
whereas silencing of b-TrCP by siRNA reduced NFnB acti-
vation and chemoresistance in pancreatic cancer cells [104].
Transgenic mice with b-TrCP1–targeted expression in the
intestine, liver, and kidney had an increased incidence of
tumor formation in these organs [105]. Conversely, silencing
b-TrCP1 through siRNA or overexpression of dominant-
negative mutant was shown to suppress the growth and
survival of human breast cancer cells [106]. In the case of
SAG, the second member of ROC/Rbx family and a RING
component of SCF [76,107], its overexpression protected
cells and tissues from apoptosis induced by redox reagents
and by ischemia/reperfusion–generated hypoxia in a RING
domain–dependent manner [107–110]. SAG overexpres-
sion also promotes cell growth under serum-starved condi-
tions [111], whereas antisense SAG transfection inhibits
tumor cell growth [112].
Although substantial progress has beenmade in this area,
SCFE3 ligase as a cancer target suffers from several intrinsic
drawbacks. The first is specificity. The same SCF E3 ligase
can promote the degradation of either oncogenes or tumor-
suppressor genes, dependent on different F-box proteins or
even the same F-box protein [13]. The therapeutic outcome
of ligase inhibitors has to be cell context–dependent, which
is hard to manage in cancer patients without a thorough
understanding of the mechanism. Secondly, assay com-
plexity is a big issue, although several screening assays for
E3 ligase inhibitors have been developed recently [113]. SCF
is a multiple component E3 ligase, and its intrinsic enzymatic
mechanism is still unclear, except that the core ligase com-
ponents Rbx1/ROC1–Cullins have been shown to promote
autoubiquitination in an in vitro assay [114–116]. Indeed, it is
feasible to identify general inhibitors against Cul–ROC/SAG
core E3 ligase using an in vitro assay described for the
inhibitor screening of APC2/APC11 core ligase [117]; such
inhibitors would not, however, have a desired specificity
against any particular SCF complex. It is uncertain to conduct
high-throughput screening (HTS) using all SCF E3 compo-
nents because, unlike kinases or proteases, SCF ligase does
not contain an evident central enzymatic active site to which
small molecules could bind. A three-dimensional structure-
based computer design strategy has been proposed to
assess whether interfaces among SCF components are
suitable for small-molecule binding [118]. An alternative
approach is to screen for inhibitors that disrupt binding
between SCF components. One example is the development
of an HTS assay for inhibitors of Cks1–Skp2 interaction that
would lead to p27 accumulation [119,120]. Figure 4 illustrates
two potential approaches to target SCF–Skp2 E3 ligase with
the expected outcome of p27 accumulation and growth
inhibition. Nevertheless, it appears that SCF E3 ligase itself
may not be a practical target per se. However, its compo-
nents may serve as cancer biomarkers for further develop-
ment and use in cancer clinics (see below).
Ligase and Their Components as Cancer Biomarkers
Early diagnosis and treatment of cancer would significantly
improve the survival of cancer patients. The development
of cancer biomarkers for early detection or prognosis pre-
diction is of significant importance. An ideal cancer bio-
marker will meet some criteria for a cancer target (e.g., high
expression in cancer tissues, but not in normal tissues, with a
causal relationship with cancer genesis, development, or
metastasis). In addition, it should be a secretory protein that
is readily obtained and identified from a patient’s body fluids,
such as serum, urea, stool, and sputum. For intracellular
biomarkers to which E3 ubiquitin ligases belong, it should
be overexpressed or it should have a high frequent mutation
rate so that it can be readily identified by immunohisto-
chemical or mutational analyses using tumor tissues from
biopsy. Traditional biomarkers of cell proliferation, such as
Ki-67 and PCNA, have had a mixed clinical track record
[121]. New and more reliable cancer markers are being
searched and developed [122]. Due to the overexpression
of some E3 ubiquitin ligases in a number of human cancers
with associated poor prognosis [13,123], it is possible that
these E3 ligases (such as Hdm2 and the F-box protein
Skp2) can be further characterized and developed as useful
cancer biomarkers.
Hdm2
Although it is normally expressed at a low level, Hdm2 is
overexpressed through gene amplification, increased tran-
scription, or enhanced translation in a variety of human
cancers, including breast carcinomas, soft tissue sarcomas,
esophageal carcinomas, lung carcinomas, glioblastomas,
and malignant melanomas [123–125]. Among the 28 human
tumor types examined, the overall frequency of Hdm2 gene
amplification is 7%, with the highest frequency being ob-
Figure 4. Targeting SCF–Skp2 for p27 accumulation and growth inhibition.
SCF E3 ubiquitin ligase consists of four components: scaffold protein Cullins to
link Skp1 and Rbx/SAG; adaptor protein Skp1 to link Cullins and F-box protein;
RING protein Rbx/ROC/SAG to recruit E2; and F-box protein to recognize
substrate. In the SCF–Skp2 E3 ligase that promotes the ubiquitination and
degradation of p27, a small protein Cks1 is also involved. Small molecules that
can either inhibit core E3 ligase activity (E3I) or disrupt CKs1/Skp2/p27 binding
would induce p27 accumulation and cause growth arrest.
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served in soft tissue tumors (20%) [125]. Furthermore, high
Hdm2 levels are often associated with poor prognosis,
with an increased likelihood of distant metastases and with
a poor response to therapeutic drugs [124,126]. Due to the
important role of Hdm2 in promoting the degradation of
tumor suppressor p53, the development of Hdm2 as a
cancer biomarker, particularly in soft tissue sarcomas, is
highly desirable.
IAPs
The expression and prognostic significance of RING-
containing IAPs, such as XIAP, c-IAP1, and c-IAP2, have
been extensively studied in human tumor and cells lines
with mixed results. The study with 60 NCI cancer cell lines
revealed that higher levels of XIAP or c-IAP1 proteins cor-
related with sensitivity or resistance to some chemothera-
peutic drugs, respectively. Conversely, acute myeloid
leukemia (AML) patients with lower levels of XIAP proteins
had a significantly longer survival, with a tendency toward a
remission longer than that of patients with higher levels of
XIAP [127]. Similarly, high expression levels of XIAP corre-
lated with poor overall survival in childhood de novo AML
[128]. In another study, however, expression levels of XIAP
had no prognostic impact on AML patients [129]. In radically
resected non–small cell lung cancer patients, a high XIAP
predicted a longer overall survival [130]. In cervical carci-
noma, the basal expression levels of IAPs had no prognostic
significance [131]. In clear cell renal carcinomas, a signifi-
cant inverse correlation was achieved between XIAP ex-
pression and tumor aggressiveness, and patients’ survival
[132]. Furthermore, survivin, a RING-less IAP, was found to
be overexpressed in most common human cancers, but not
in normal terminally differentiated adult tissues. The resis-
tance of cancer cells to conventional cancer therapy and a
worse clinical prognosis are usually correlated with a high
expression of survivin [39,49,133–136]. Due to these mixed
results, it is unlikely that IAPs, with the probable exception
of survivin, will be developed as useful cancer biomarkers.
SCF Components: Skp2, -TrCP, Cul4A, and SAG
It has been well documented that Skp2 acts as an oncogene
mainly by targeting p27 for ubiquitination and degradation
[137]. Overwhelming evidence showed that Skp2 is over-
expressed in almost all major human cancers, including
carcinomas of the breast, colon, lung, brain, prostate, and
liver, amongmany other human cancers. Inmost cases, Skp2
overexpression is inversely correlated with p27 expression
and is directly correlated with poor clinic prognosis (for a
review, see Nakayama and Nakayama [13]). Thus, Skp2–
p27 inverse correlation may deserve further characterization
for clinical use as a prognostic index.
Among other SCF components, expression of b-TrCP1
was found to be elevated in colon cancers (particularly in
those with metastases) [138], pancreatic carcinomas [104],
and hepatoblastomas [139]. Overexpression of b-TrCP2 was
also detected in primary prostate, breast, and gastric can-
cers, as well as in the cell lines derived from these cancers
[140–142]. Cul4A was recently found to be involved in
Mdm2-mediated p53 degradation [143], as well as in
DDB1–Skp2–mediated p27 degradation [144]. Cul4A gene
was amplified and overexpressed in primary breast cancers
[145] and hepatocellular carcinomas [146]. Finally, SAG was
overexpressed in a subset of colorectal carcinomas [112] and
in non–small cell lung cancers [147]. Importantly, high SAG
expression was correlated with poor patient survival and
could serve as a useful prognostic marker [147].
Conclusion and Perspectives
E3 ubiquitin ligases regulate a variety of biologic processes,
including cell growth and apoptosis, through the timely ubiq-
uitination and degradation ofmany cell cycle– and apoptosis-
regulatory proteins. Abnormal regulation of E3 ligases has
been convincingly shown to contribute to cancer develop-
ment [12,13,148]. Thus, targeting E3 ubiquitin ligases for
cancer therapy has gained increasing attention, which is
further stimulated by the recent approval of a general protea-
somal inhibitor, bortezomib (Velcade, Millennium, MA), for
the treatment of relapsed and refractory multiple myeloma
[149], as well as for the discovery of a new class of protea-
some inhibitors [150]. In contrast to general proteasome
inhibitors, targeting a specific E3 would selectively stabilize
a specific cellular protein regulated by a particular E3, thus
avoiding some unwanted effects on other cellular proteins.
This would, therefore, achieve a high level of specificity with
less (at least in theory) associated toxicity. Because several
HTS assays are now in place for the rapid screening of small
molecular inhibitors of E3 ligases [113], it is anticipated that, in
the near future, specific inhibitors of E3 ubiquitin ligase will be
discovered and developed as a novel class of anticancer
drugs. E3-based cancer biomarkers will be also developed
and used in clinics as diagnostic tools or prognostic indices
for the benefit of cancer patients.
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